Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topiramate for smoking cessation.

Yasser Khazaal1, Jacques Cornuz, Romain Bilancioni

  • 1University Department of Adult Psychiatry, Prilly, and Department of Community Medicine and Public Health, University Hospital, Lausanne, Switzerland. yasser.khazaal@hospvd.ch

Psychiatry and Clinical Neurosciences
|May 31, 2006
PubMed
Summary

Topiramate, an alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate antagonist, shows promise in addiction treatment. Preliminary results indicate topiramate aided smoking cessation in some participants, though side effects were noted.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revue medicale suisse·2026
Same author

Electronic cigarette for smoking cessation: a fast-track Delphi consensus of French-speaking experts.

Archives of public health = Archives belges de sante publique·2025
Same author

[Treatment for smoking cessation : situation in 2025].

Revue medicale suisse·2025
Same author

[Health promotion and prevention in municipalities : levers and actions].

Revue medicale suisse·2025
Same author

Revue medicale suisse·2025
Same author

Revue medicale suisse·2025

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Medicine

Background:

  • Topiramate exhibits AMPA/kainate antagonism, suggesting potential utility in addiction treatment.
  • Smoking cessation remains a significant public health challenge, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To investigate the efficacy of flexible-dose topiramate as an aid for smoking cessation.
  • To evaluate the impact of topiramate on cigarette consumption and abstinence rates.

Main Methods:

  • A flexible-dose topiramate regimen was administered to 13 adult smokers.
  • Participants included individuals seeking to quit smoking and those using topiramate for other conditions.

Main Results:

  • Six of 13 smokers achieved abstinence at 2 months.

Related Experiment Videos

  • Two additional smokers reduced cigarette consumption by over 50%.
  • Temporary reduction in smoking often preceded abstinence, but side effects led to treatment discontinuation in three participants.

    • Conclusions:

    • Topiramate demonstrates preliminary efficacy in supporting smoking cessation and reducing cigarette consumption.
    • Further controlled trials are warranted to validate these findings and assess long-term safety and effectiveness.
    • Intolerable side effects represent a potential limitation for some individuals undergoing topiramate treatment for smoking cessation.